Making Waves: PaxMedica In The Spotlight; Bullish View On Outbrain
- July 24th, 2023
- 451 views
Shares of PaxMedica, Inc. (Nasdaq: PXMD) surged over 10% in pre-market trading as the company revealed positive top-line data from its PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).
The study's primary endpoint was successfully achieved, showing statistically significant and clinically meaningful results. This breakthrough opens the path for an NDA filing for the use of PAX-101 (intravenous suramin) to treat African Sleeping Sickness.
$PXMD currently stands at $0.92 in pre-market, reflecting a gain of $0.12 (+15.15%) following the announcement.
In other news, Outbrain Inc. (Nasdaq: OB), a leading content discovery platform, received a positive review from Needham, which maintained its "Buy" rating on the stock and raised the price target from $5.5 to $6.5.
With Friday's closing price of $5.17, the updated price target suggests a potential upside of $1.33 or approximately 25.7%, according to the brokerage firm's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login